Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression.
We report the case of a patient with subacute cerebellar degeneration presenting as paraneoplastic syndrome, preceding the final diagnosis of breast cancer. The tumor had high HER2 overexpression, so a weekly regimen of paclitaxel/trastuzumab was started after surgery of the primary breast tumor. Negativity of specific antineuronal antibodies and clinical stabilization of the patient was achieved after 12 cycles of treatment. The interest of this case is the unusual presentation and the targeted therapeutic approach that has been used.
Sancho
M Isabel Gallegos
MI
Servicio de Oncologia Medica, Hospital Universitario Juan Canalejo-Maritimo de Oza, La Coruna, Spain. isagalls@yahoo.es
Lopez
M Reboredo
MR
Martinez
L Calvo
LC
Campelo
R Garcia
RG
Facal
M S Lopez
MS
Budino
B Sanroman
BS
Varela
M Quindos
MQ
Novoa
S Antolin
SA
Ayerbes
M Valladares
MV
Curbera
G Alonso
GA
Aparicio
L M Anton
LM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D020362:Paraneoplastic Cerebellar Degeneration / Q000175:diagnosis* / Q000188:drug therapy; D049268:Positron-Emission Tomography; D017698:Postmenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D018570:Risk Assessment; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab